darglitazone has been researched along with Obesity in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andresen, SM; Bamberg, K; Dalen, KT; Gustafsson, JA; Haugen, F; Hollung, K; Jacinto, S; Juvet, LK; Nebb, HI; Schuster, GU; Tobin, KA; Ulven, SM | 1 |
| Ferguson, DC; Hoenig, M | 1 |
| Boden, G; Chaiken, RL; Eckert-Norton, M; Gelfand, RA; Lebovitz, HE; Pasmantier, R; Ryan, I | 1 |
| Jacinto, SM; Ljung, B; Oakes, ND; Thalén, PG | 1 |
1 trial(s) available for darglitazone and Obesity
| Article | Year |
|---|---|
Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Thiazoles; Thiazolidinediones | 1995 |
3 other study(ies) available for darglitazone and Obesity
| Article | Year |
|---|---|
On the role of liver X receptors in lipid accumulation in adipocytes.
Topics: Adipocytes; Adipose Tissue; Animals; Anticholesteremic Agents; CCAAT-Enhancer-Binding Proteins; Cells, Cultured; Desmosterol; DNA-Binding Proteins; Fatty Acid Synthases; Female; Gene Expression Regulation; Humans; Hydrocarbons, Fluorinated; Lipid Metabolism; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Orphan Nuclear Receptors; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Up-Regulation | 2003 |
Effect of darglitazone on glucose clearance and lipid metabolism in obese cats.
Topics: Animals; Blood Glucose; Cat Diseases; Cats; Female; Glucose Tolerance Test; Insulin; Obesity; Ovariectomy; Thiazolidinediones | 2003 |
Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Fasting; Fatty Acids, Nonesterified; Glucose Clamp Technique; Humans; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Kinetics; Lipid Mobilization; Lipoproteins, VLDL; Liver; Male; Metabolic Clearance Rate; Muscle, Skeletal; Obesity; Oxidation-Reduction; Polyethylene Glycols; Postprandial Period; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 2001 |